Post by
colima on Mar 19, 2020 7:55pm
Patients Treated; RAPID KNOWN RESULTS (Frm: China study)
The primary safety outcome Before the MSC transplantation, the patients had symptoms of high fever (38.5 0.5), weakness, shortness of breath, and low oxygen saturation. However, 2~4 days after transplantation, all the symptoms disappeared in all the patients, the oxygen saturations rose to 95% at rest, without or with oxygen uptake (5 liters per minute). In addition, no acute infusion-related or allergic reactions were observed within two hours after transplantation. Similarly, no delayed hypersensitivity or secondary infections were detected after treatment.
Comment by
colima on Mar 19, 2020 8:16pm
. Leng Z, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and Disease, 10.14336/AD.2020.0228 ( ALL LBL investors should read this study.) !!!!!!!!!!!!!!!
Comment by
Freechemicals on Mar 19, 2020 8:41pm
This post has been removed in accordance with Community Policy
Comment by
Joecanada13 on Mar 19, 2020 9:35pm
https://www.aginganddisease.org/EN/10.14336/AD.2020.0228
Comment by
In2Dollars on Mar 20, 2020 7:49am
This post has been removed in accordance with Community Policy
Comment by
colima on Mar 19, 2020 9:47pm
To read the full study:. Leng Z, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and Disease, 10.14336/AD.2020.0228
Comment by
Freechemicals on Mar 19, 2020 9:59pm
This post has been removed in accordance with Community Policy
Comment by
MasterBlasters on Mar 20, 2020 2:36am
This post has been removed in accordance with Community Policy